At ELECTRONICA, ITEN Present an Autonomous Asset Monitoring Solution Based on a 100µA.h Micro-Battery!
10.11.2022 18:55:00 EET | Business Wire | Press release
ITEN, the deep tech company, which just closed a financing round of 80M€ to become a key player in the manufacture of solid-state lithium-ion micro-batteries, shall take the opportunity of next ELECTRONICA exhibition to present a breakthrough in the way of powering autonomous embedded systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005719/en/
Ecofriendly and powerful soli-state micro-battery able to recharge in a few minutes. (Photo: ITEN)
When observing the battery-powered electronic solutions, ITEN came indeed to the following conclusions:
- A lot of electronic designs relies on very polluting coin cells, difficult to assemble on Printed Circuit Boards, costly to recycle and requiring periodic maintenance to replace the battery once empty.
- Depending on the countries, only 30 to 50% of such coin cells are effectively recycled.
- Autonomous embedded systems require less and less energy to operate; however, from time to time, the power supply must deliver high current pulses for instance to drive RF transceivers or actuators; therefore, most electronic designers must use oversized coin cells because such batteries are known to deliver only small currents.
From a battery standpoint, this means that a lower battery capacity could be used if the battery would be able to deliver the required power and could be recharged regularly.
This is precisely what ITEN shall demonstrate during ELECTRONICA: ITEN shall indeed present an autonomous asset monitoring solution, including sensors and a Bluetooth Low Energy (BLE) System-on-a-chip, and powered by the combination of an indoor photovoltaic cell from DRACULA Technologies (LAYERR Technology) and ITEN’s powerful rechargeable SMD micro-battery of only 100µA.h. The solution operating 24/7 can send data every 10 seconds during the day and every 4 to 5 minutes during the night (this frequency could be increased if using a 250µA.h micro-battery instead). By comparison, a coin cell of at least 100mA.h would be required to get the same operating conditions but with a limited lifetime.
By extension, similar designs could be used in applications like BLE asset tracking, BLE tags, beacons, and sensor data loggers.
On stand B4-120, ITEN shall also demo micro-batteries used as a back-up power supply to keep some clocks or microcontrollers active or to send maintenance alerts in case of failure of the main power source.
By doing so, ITEN clearly reassert their strategy to progressively replace most of the coin cells used worldwide by ecofriendly rechargeable SMD micro-batteries containing neither heavy metals, nor toxic materials, nor organic solvents and showing a carbon footprint 200 to 1000 times less compared to coin cells.
After 8 years of R&D, ITEN have been granted more than 200 patents worldwide. ITEN are an integrated device manufacturer, controlling the complete production chain from nanomaterial synthesis up to the battery packaging and test. Even with low capacities, ITEN micro-batteries can deliver power and high current pulses. They are a concrete response to electronics designers looking for ecofriendly alternatives to coin cells. In this respect, ITEN solutions fit in with the European Directive recommending getting rid of non-rechargeable batteries in all electronic system designs from year 2030.
About ITEN:
ITEN is the leading company developing and manufacturing ecofriendly solid-state lithium-ion SMD micro batteries. Such micro batteries are rechargeable In a few minutes and can deliver power over a wide operating temperature range. They are used in many applications as back-up power supply, or to power autonomous sensor nodes or in applications like tracking and monitoring, smartphone peripherals, smart cards, medical devices, home and building automation, smart cities, wearables, and e-textiles.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005719/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
